TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07295821: Phase II, Single-arm Multicenter Study of Osimertinib Induction Before Radiotherapy and Maintenance in Chemo-ineligible or Refusing Patients With Stage III, Unresectable NSCLC and EGFR Mutation-positive Tumors

Sponsor: AstraZeneca · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07295821 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07295821 Rescue Dossier →